Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.72 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | CTSC | P53634 | 8/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | BLK | P51451 | 1/20 | 0.58 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.58 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.58 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196171 | 0.94 | EGFR (0.81) | EGFREML4ALKCTSCPLK4 | |
| SCHEMBL16206979 | 0.91 | EGFR (0.87) | EGFREML4ALKCTSCJAK2 | |
| SCHEMBL16206717 | 0.89 | ALK (0.68) | EGFREML4ALKPLK4GAK | |
| SCHEMBL16207323 | 0.89 | EGFR (0.79) | EGFREML4ALKPLK4GAK | |
| SCHEMBL16206696 | 0.85 | ALK (0.63) | EGFREML4ALKPLK4GAK | |
| SCHEMBL16206999 | 0.85 | EGFR (0.72) | EGFREML4ALKFLT3 | |
| SCHEMBL16195522 | 0.84 | EGFR (1.00) | EGFRCTSCNUAK1JAK2BLK | |
| SCHEMBL16207003 | 0.84 | EGFR (0.89) | EGFREML4ALKCTSCJAK2 | |
| SCHEMBL16207309 | 0.82 | EGFR (0.90) | EGFREML4ALKCTSCPLK4 | |
| SCHEMBL16195665 | 0.82 | EGFR (1.00) | EGFREML4ALKCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885EML4 158/4885ALK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.